By Michael J. Critelli | MakeUsWell Newsletter,
Over the past two years, the meteoric rise of GLP-1 drugs like Ozempic, Wegovy, and Mounjaro has disrupted not only healthcare but also the food industry’s quiet science of seduction. These medications suppress appetite, slow digestion, and blunt the dopamine rewards associated with overeating. For millions of users, they represent liberation from a lifelong biochemical trap—one that food scientists have spent decades perfecting.
Within the last week, their importance in population health has been underscored by an attempt by the Trump Administration to negotiate a price of $149 a month, far below their current pricing to large commercial insurance plans and employers.
But as with any innovation that changes human behavior, there is a counter-move underway. In the same way marketers learn to outwit ad blockers and hackers evolve to bypass new security systems, food manufacturers are experimenting with reformulations to preserve the allure of their most profitable products. This is not a morality play with heroes and villains. It is a systems-level conflict between two forms of applied science: one medical, one culinary; one designed to quiet appetite, the other to awaken it.